Northway Biotech

What Northway Biotech does

Northway Biotech (legal entity Biotechpharma UAB) is a privately held, end-to-end contract development and manufacturing organization (CDMO) founded in 2004 in Vilnius, Lithuania, and operating as part of the Northway Group of 17 enterprises. The company specializes in protein-based biologics and gene therapies, offering a vertically integrated service portfolio that spans cell line development, upstream and downstream process development, analytical methods development, formulation, viral clearance studies, cell banking, cGMP drug substance manufacturing, and aseptic fill-finish. A distinguishing technical feature is its dual mammalian cell culture and microbial fermentation expression capability, supported by 40 bioreactors, six mammalian cGMP lines up to 4,000L, four microbial lines up to 3,000L, 24 HPLCs, six mass spectrometers, and recently expanded BSL-2 and BSL-3 laboratory infrastructure. The company runs three state-of-the-art facilities — two in Vilnius (including Bio City I, II, and III) and one in Waltham, Massachusetts (opened 2020) — and employs more than 200 highly qualified specialists across the biotechnology cluster.

Northway Biotech generates revenue through project-based contract development and manufacturing services sold directly to international pharmaceutical and biotechnology companies, including EU- and US-listed corporations and clinical-stage biotechs. It has served more than 100 clients and completed over 205 projects, with 70% of its customer base in Europe and 30% in the US. Sales are executed through a dedicated business development team (including a VP of Business Development) supported by conference participation, content marketing, LinkedIn presence, and direct enterprise outreach, with no reseller or distributor channel. Pricing is bespoke and quote-based rather than published, consistent with custom CDMO engagements. The company is pursuing a multi-year capital-intensive expansion — anchored by the €7B Bio City campus plan, the €50M Gene Therapy Centre opened in 2024, and a €61M Cell Therapy and Personalized Medicine Center announced in 2026 — alongside non-dilutive financing from EU R&D grants and loans from ILTE, Citadele, and NIB. Leadership is founder-led by Prof. Vladas Algirdas Bumelis (former Sicor Biotech/Teva executive), and the firm has received both the 2025 Outsourced Pharma CDMO Leadership Awards (Global and Europe Biologics categories) and multiple regional awards for biotechnology leadership.

Name

Northway Biotech

Legal name

Biotechpharma UAB

Website

https://northwaybiotech.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

Northway Biotech is a Lithuania-based, end-to-end biologics CDMO serving global pharmaceutical and biotechnology companies with vertically integrated services spanning cell line development through cGMP drug substance and aseptic fill-finish, using both mammalian and microbial expression systems across facilities in Vilnius and Waltham, MA.

Ownership category

akta.pro rank

Product category

Biologics Contract Development and Manufacturing (CDMO)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Cell Therapy CDMO (HLAGABAD), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Biologics CDMO
• Contract manufacturing services
• Gene therapy development
• Mammalian cell culture
• Microbial fermentation

Headquarters

HQ city

Vilnius

HQ country

Lithuania

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Contract Development and Manufacturing Services (CDMO): Northway Biotech generates revenue through providing end-to-end contract development and manufacturing services for biopharmaceutical companies. Services span from cell line development and process development through to cGMP manufacturing of drug substance and drug product. The company serves international pharmaceutical and biotechnology corporations, including companies listed on European and US stock exchanges. Revenue is project-based, with engagements ranging from preclinical to commercial-scale manufacturing.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Northway Biotech is an end-to-end contract development and manufacturing organization (CDMO) providing cell line development, process development (upstream and downstream), analytical methods development, formulation development, viral clearance studies, cell banking, and cGMP drug substance and drug product manufacturing for protein-based biologics and gene therapies. The company uses both mammalian cell culture and microbial fermentation expression systems, delivering project-based services from preclinical through commercial scale to international pharmaceutical and biotechnology clients.

Product overview

Northway Biotech is an end-to-end contract development and manufacturing organization (CDMO) specializing in protein-based biologics and gene therapies. The company operates a vertically integrated service model offering cell line development, process development (upstream and downstream), analytical methods development, formulation development, viral clearance studies, cell banking, drug substance manufacturing (mammalian and microbial), and drug product fill-finish services. Quality and regulatory affairs support is provided alongside manufacturing operations. The company has 3 state-of-the-art facilities in Vilnius, Lithuania and Waltham, MA, USA, with capabilities for preclinical through commercial-scale production.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell Line Development Development of mammalian and microbial cell lines and strains for monoclonal antibodies and recombinant proteins, including single-cell cloning with analytical confirmation and stability studies, offered to pharmaceutical and biotechnology clients.
• Process Development (USP & DSP) Upstream process (USP) and downstream process (DSP) development for biologics, pDNA, AAV, AV, and LV vector production, including process optimization, rapid technology transfer, scale-up, and formulation development for pharmaceutical and biotechnology clients.
• Analytical Methods Development Development, qualification, and validation of assays for recombinant proteins, monoclonal antibodies, pDNA, and viral vectors, including liquid chromatography, electrophoresis, spectroscopic analysis, particle analysis, LC-MS/MS, and cell-based biological assays.
• Formulation Development Formulation development for liquid and lyophilized drug product in vials or prefilled syringes, including stress and accelerated stability studies and shelf-life estimation for pharmaceutical and biotechnology clients.
• Viral Clearance Studies Full-service Viral Clearance Studies (VCS) to validate the effectiveness of purification processes in removing or inactivating viral contaminants, compliant with ICH Q5A(R2) guidelines and FDA/EMA expectations, using six BSL-2 laboratories and BSL-3 capable facilities.
• Cell Banking cGMP Master and Working Cell Banks (MCB/WCB) manufacturing for microbial and mammalian cultures, including characterization and testing according to ICH Q5B, Q5D, Q5A, Q6B, and Q7 guidelines.
• Drug Substance Manufacturing cGMP drug substance manufacturing based on both microbial fermentation technology and mammalian cell culture, with 6 mammalian production lines up to 4000L working volume and 4 microbial production lines up to 3000L, delivered across separate manufacturing lines in Vilnius and Boston.
• Drug Product (Fill-Finish) Aseptic fill-finish of sterile drug product into vials, pre-filled syringes, and cartridges, with liquid and lyophilized formulations in Grade A environment per EMA and FDA requirements, with batch sizes up to 20,000 vials, 19,000 pre-filled syringes, or 19,000 cartridges.
• Quality Assurance QA oversight ensuring cGMP compliance, staff training, internal and external audits, corrective and preventative actions, documentation management, and approval of intermediates, drug substances, and drug products.
• Quality Control QC testing ensuring products meet predefined criteria through advanced techniques demonstrating physical and chemical characteristics, including environmental monitoring and process control.
• Regulatory Affairs CMC documentation preparation for INDs/IMPDs and BLAs/MAAs, compliance confirmation, quality and safety reviews, and regulatory submission support for pharmaceutical and biotechnology clients.

Quantifiable outcome

• Viral Clearance Studies delivered in under 10 weeks with 2 model viruses, and 12 weeks with 4 model viruses — over 1 month faster than industry standards
• +4 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Ten partnerships are on record, tiered core, strategic and major.

• Kamieninių ląstelių tyrimų centras (Stem Cell Research Center)coreStrategic or Co-development Partner · 1 June 2026Stem Cell Research Center, a company belonging to the Northway group of companies, is building the €61 million Cell Therapy and Personalized Medicine Center at VCIIP within the Bio City III project. It is part of the internal Northway group structure developing advanced cell therapy infrastructure.
• Lithuanian Consortium for Engagement with MITstrategicStrategic or Co-development Partner · 29 January 2026Northway Biotech joined a Lithuanian science and business consortium collaborating with MIT (Massachusetts Institute of Technology). The consortium includes 7 Lithuanian universities, 2 research institutes, and 5 business partners. Northway Biotech aims to establish a joint biotechnology research center in Lithuania combining Northway's industrial experience with MIT's academic competence. The consortium is coordinated through MIT MISTI Lithuania.
• ExpreS2ion Biotechnologies ApScoreStrategic or Co-development Partner · 28 January 2026Northway Biotech was selected as ExpreS2ion's cGMP manufacturing partner for its Nipah virus vaccine candidate. The program is part of an EU-funded Horizon Europe 'VICI-Disease' consortium coordinated by the University of Copenhagen. Manufacturing activities are planned to commence in Q1 2026 and target completion by the end of 2026. Northway was chosen based on its established familiarity with ExpreS2ion's recombinant protein vaccine platform and successful execution of a closely related vaccine program.
• Diorasis TherapeuticscoreStrategic or Co-development Partner · 29 July 2025Strategic partnership for the development and manufacturing of AAV gene therapy for glaucoma (DT003). Northway Biotech leverages its 20 years of biologics manufacturing experience to develop a robust, compliant process for pre-clinical and clinical material production. The partnership includes AAV process development, analytical method development, pre-clinical manufacturing, and clinical manufacturing of cGMP drug substance and drug product.
• AATec Medical GmbHcoreStrategic or Co-development Partner · 15 July 2025Partnership for manufacturing process development and analytical development of ATL-105, a proprietary inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis. Northway Biotech leverages its microbial systems expertise (Pichia pastoris expression system) to develop and scale the production process. ATL-105 combines anti-protease, anti-inflammatory, and anti-infective properties in one molecule.
• Kaida BioPharmacoreStrategic or Co-development Partner · 21 May 2025Manufacturing agreement for KAD101, Kaida's lead product candidate — a novel biologic prolactin receptor antagonist targeting hormone-driven cancers affecting women (initially ovarian cancer). Northway Biotech is developing a robust manufacturing process, analytical methods, formulation optimization, production scaling, and cGMP drug substance batch manufacturing for Phase 1 clinical studies.
• Micreos Pharmaceuticals AGcoreStrategic or Co-development Partner · 4 March 2025Strategic partnership to develop scalable cGMP production processes for Micreos' engineered endolysin therapeutic MEndoB, a first-in-class dual-active domain targeted medicine for atopic dermatitis. Northway Biotech is responsible for developing and validating analytical methods, cell bank manufacturing, technology scale-up for cGMP Drug Substance, and IND/IMPD supporting documentation preparation.
• Mallia Therapeutics GmbHcoreStrategic or Co-development Partner · 4 February 2025Partnership for the development of production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth for hair loss (androgenetic alopecia and alopecia areata). Northway Biotech utilizes the Pichia pastoris expression system and includes development of analytical methods, technology scale-up, and cGMP Drug Substance manufacturing.
• NarestamajorImplementation/ SI/ Consulting Partner · 4 February 2025Naresta, one of Lithuania's largest construction companies, completed construction of the 1,700 sq m logistics centre for the Stem Cell Research Center in just 9 months. This is the second joint project between Naresta and the Northway group. Naresta also built the Gene Therapy Centre (Celltechna) — the first gene therapy centre in the Baltic States.
• BiotechamajorImplementation/ SI/ Consulting Partner · 26 September 2024Biotecha, a company specializing in life sciences and pharmaceutical manufacturing, was responsible for the installation of laboratories and the entire infrastructure at the Gene Therapy Centre (Celltechna) in Bio City II.

Scale indicators18 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Lonza Group: Global leader in biologics CDMO services with mammalian and microbial capabilities across the full development and commercial manufacturing lifecycle. Comparable to Northway as a vertically integrated biologics CDMO serving pharma/biotech clients worldwide, but with substantially larger scale (10,000–20,000L bioreactors) and broader service breadth.
• Samsung Biologics: Large-scale biologics CDMO offering end-to-end services from cell line to commercial drug product, with mega-scale bioreactor capacity. Comparable to Northway in offering mammalian cell culture CDMO and integrated services, but operates at materially larger commercial scale and is headquartered in South Korea with global facilities.
• WuXi Biologics: Global biologics CRDMO with comprehensive services spanning discovery, development, and manufacturing of mAbs, recombinant proteins, and viral vectors. Directly comparable to Northway's end-to-end biologics CDMO model, particularly on mammalian expression platforms and gene therapy vector capabilities, though at significantly larger scale.
• Catalent: Major global CDMO with biologics and cell/gene therapy capabilities, including fill-finish and viral vector services. Comparable to Northway in providing mammalian biologics manufacturing, fill-finish, and gene therapy offerings, but with broader modality coverage and significantly larger commercial footprint.
• Thermo Fisher Scientific (Patheon CDMO): Global CDMO with biologics manufacturing, viral vector services, fill-finish, and clinical/commercial supply capabilities. Comparable to Northway in biologics drug substance and drug product services, but with vastly greater scale and broader pharmaceutical services portfolio.

Direct peers

• AGC Biologics: Mid-sized global CDMO offering mammalian and microbial biologics manufacturing, gene therapy (AAV/lentiviral), and cell therapy services from cell line to commercial supply. Closely comparable to Northway in scale, dual expression platform strategy, and ATMP/gene therapy focus, though with a broader multi-continent facility footprint.
• Rentschler Biopharma: European-headquartered biologics CDMO specializing in mammalian cell culture, microbial expression, and gene therapy/ATMP services with integrated process development and cGMP manufacturing. Closely comparable to Northway in size, European base, dual expression platform strategy, and ATMP capability expansion.
• Polpharma Biologics: European biologics CDMO with mammalian cell culture and microbial fermentation capabilities, providing biosimilar and novel biologic development and manufacturing. Comparable to Northway as a mid-sized European CDMO with dual expression systems, biosimilar expertise, and integrated services from cell line to drug product.
• Biovian: European GMP CDMO specializing in microbial and mammalian biologics manufacturing, viral vector production, and ATMP services. Comparable to Northway as a mid-sized Northern European CDMO with dual expression systems and gene therapy focus, serving similar biotech and pharma customers.

Emerging players

• Celltrion: South Korean biopharmaceutical company with biosimilars and biologics manufacturing capabilities, including mammalian cell culture CDMO offerings. Comparable to Northway in biosimilar monoclonal antibody expertise and mammalian biologics manufacturing, though more focused on in-house product development than third-party CDMO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/northwaybiotech
• Xx.com/northwaybiotech
• Facebookfacebook.com/NorthwayBiotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries6 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Northway Biotech